Loading…

READY TO ROCK?

Click the button below to start exploring our website and learn more about our awesome company
Start exploring

Onconova Therapeutics (NASDAQ: ONTX) Reduced to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was reduced by Zacks  from a “buy” rating to a “hold” ranking in a research note released to capitalists on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm. It focuses on finding and establishing little particle drug candidates to treat cancer cells. The Business‘s products under different stages of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research analysts also recently commented on the company. Noble Financial reissued a “acquire” score and released a $11.00 cost goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “buy” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. The business has a 50 day moving typical cost of $2.90 as well as a two-hundred day relocating average rate of $4.16. The company has a market cap of $46.76 million, a P/E ratio of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits results on Thursday, November 11th. The biopharmaceutical firm reported ($ 0.22) incomes per share for the quarter, topping analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as an adverse web margin of 8,294.27%. The company had income of $0.06 million during the quarter, compared to the consensus price quote of $0.06 million. Throughout the same quarter in the previous year, the firm published ($ 0.45) EPS. As a group, research analysts anticipate that Onconova Therapeutics will upload -1.18 EPS for the present year.

A number of hedge funds have actually just recently bought and sold shares of ONTX. GSA Resources Allies LLP acquired a brand-new position in Onconova Therapeutics throughout the third quarter worth $922,000. Hudson Bay Resources Monitoring LP purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a brand-new setting in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC acquired a brand-new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP acquired a new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds as well as other institutional financiers have 13.36% of the business’s stock.

Regarding Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the identification and growth of oncology therapeutics. It concentrates on finding and also establishing little particle medicine prospects to treat cancer cells. The business was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 as well as is headquartered in Newtown, PA

. Get a free duplicate of the Zacks research record on Onconova Therapeutics (ONTX).

To learn more about research offerings from Zacks Investment Research, see Zacks.com.

This instantaneous news alert was generated by narrative scientific research modern technology and economic information from Market in order to provide viewers with the fastest and most exact reporting. This story was reviewed by Market’s content team prior to publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS NOW?

Prior to you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market monitors Wall Street’s premier as well as best performing research analysts as well as the stocks they advise to their clients each day. Market has actually recognized the 5 stocks that cover experts are quietly whispering to their customers to acquire currently prior to the wider market catches on … as well as Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics presently has a “Buy” score among experts, premier experts think these five stocks are better buys.